{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:59:20Z","timestamp":1793289560832,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jhep.2017.11.024","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T09:31:21Z","timestamp":1511515881000},"page":"827-837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":136,"title":["Clinical management of polycystic liver disease"],"prefix":"10.1016","volume":"68","author":[{"given":"Ren\u00e9 M.M.","family":"van Aerts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyanne F.M.","family":"van de Laarschot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus M.","family":"Banales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost P.H.","family":"Drenth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2017.11.024_b0005","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrgastro.2012.254","article-title":"Diagnosis and management of polycystic liver disease","volume":"10","author":"Gevers","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.11.024_b0010","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/2050640615618042","article-title":"Creating an effective clinical registry for rare diseases","volume":"4","author":"D'Agnolo","year":"2016","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhep.2017.11.024_b0015","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/tri.12875","article-title":"Center is an important indicator for choice of invasive therapy in polycystic liver disease","volume":"30","author":"D'Agnolo","year":"2016","journal-title":"Transplant Int"},{"key":"10.1016\/j.jhep.2017.11.024_b0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2015.59","article-title":"Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"88","author":"Chapman","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.jhep.2017.11.024_b0025","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrgastro.2014.155","article-title":"Polycystic liver diseases: advanced insights into the molecular mechanisms","volume":"11","author":"Perugorria","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.11.024_b0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.molmed.2014.01.003","article-title":"Polycystic liver disease: ductal plate malformation and the primary cilium","volume":"20","author":"Wills","year":"2014","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jhep.2017.11.024_b0035","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1172\/JCI90129","article-title":"Isolated polycystic liver disease genes define effectors of polycystin-1 function","volume":"127","author":"Besse","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2017.11.024_b0040","doi-asserted-by":"crossref","first-page":"40419","DOI":"10.1074\/jbc.M405079200","article-title":"Calcium restriction allows cAMP activation of the B-Raf\/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype","volume":"279","author":"Yamaguchi","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2017.11.024_b0045","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/j.bbamcr.2013.04.001","article-title":"N-linked protein glycosylation in the ER","volume":"1833","author":"Aebi","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jhep.2017.11.024_b0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-biophys-050511-102312","article-title":"Mechanisms of Sec61\/SecY-mediated protein translocation across membranes","volume":"41","author":"Park","year":"2012","journal-title":"Annu Rev Biophys"},{"key":"10.1016\/j.jhep.2017.11.024_b0055","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","article-title":"Wnt\/beta-catenin signaling in development and disease","volume":"127","author":"Clevers","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2017.11.024_b0060","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1053\/j.gastro.2011.08.004","article-title":"Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease","volume":"141","author":"Janssen","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.11.024_b0065","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.2010030328","article-title":"What is the role of somatic mutation in autosomal dominant polycystic kidney disease?","volume":"21","author":"Harris","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jhep.2017.11.024_b0070","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.molmed.2014.01.004","article-title":"Polycystin-1: a master regulator of intersecting cystic pathways","volume":"20","author":"Fedeles","year":"2014","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jhep.2017.11.024_b0075","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ncb3363","article-title":"The polycystin complex mediates Wnt\/Ca(2+) signalling","volume":"18","author":"Kim","year":"2016","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.jhep.2017.11.024_b0080","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jhep.2017.11.024_b0085","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/ndt\/gfw008","article-title":"Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease","volume":"31","author":"Chebib","year":"2016","journal-title":"Nephrol Dialysis Transplant"},{"key":"10.1016\/j.jhep.2017.11.024_b0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cgh.2016.06.017","article-title":"Gastrointestinal manifestations of autosomal-dominant polycystic kidney disease","volume":"15","author":"Mikolajczyk","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.11.024_b0095","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1478-3231.2007.01595.x","article-title":"Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease","volume":"28","author":"Hoevenaren","year":"2008","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.11.024_b0100","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1478-3231.2010.02247.x","article-title":"Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases","volume":"31","author":"Van Keimpema","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.11.024_b0105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1055\/s-0036-1597817","article-title":"New advances in polycystic liver diseases","volume":"37","author":"Santos-Laso","year":"2017","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2017.11.024_b0110","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrgastro.2017.69","article-title":"Genetics: Novel causative genes for polycystic liver disease","volume":"14","author":"Perugorria","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.11.024_b0115","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","article-title":"Mutations in GANAB, encoding the glucosidase IIalpha subunit, cause autosomal-dominant polycystic kidney and liver disease","volume":"98","author":"Porath","year":"2016","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jhep.2017.11.024_b0120","unstructured":"Harris PC TV. Polycystic Kidney Disease, Autosomal Dominant. 2002 Jan 10 [Updated 2015 Jun 11] In: Pagon RA, Adam MP, Ardinger HH, et al., editors GeneReviews\u00ae [Internet] Seattle (WA): University of Washington, Seattle; 1993\u20132017."},{"key":"10.1016\/j.jhep.2017.11.024_b0125","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.11.024_b0130","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1681\/ASN.2010101080","article-title":"Mutations in multiple PKD genes may explain early and severe polycystic kidney disease","volume":"22","author":"Bergmann","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jhep.2017.11.024_b0135","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.semnephrol.2015.10.003","article-title":"KHA-CARI autosomal dominant polycystic kidney disease guideline: genetics and genetic counseling","volume":"35","author":"Patel","year":"2015","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.jhep.2017.11.024_b0140","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-9-69","article-title":"J.P.H. Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management","volume":"9","author":"Cnossen","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jhep.2017.11.024_b0145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1399-0004.2009.01353.x","article-title":"Secondary and tertiary structure modeling reveals effects of novel mutations in polycystic liver disease genes PRKCSH and SEC63","volume":"78","author":"Waanders","year":"2010","journal-title":"Clin Genet"},{"key":"10.1016\/j.jhep.2017.11.024_b0150","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2215\/CJN.00080605","article-title":"Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort","volume":"1","author":"Bae","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jhep.2017.11.024_b0155","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1432-2277.2011.01360.x","article-title":"Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study","volume":"24","author":"van Keimpema","year":"2011","journal-title":"Transplant Int"},{"key":"10.1016\/j.jhep.2017.11.024_b0160","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1053\/j.gastro.2013.04.055","article-title":"Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data","volume":"145","author":"Gevers","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.11.024_b0165","first-page":"1282","article-title":"Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease","volume":"26","author":"Sherstha","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.024_b0170","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/hep.1840110619","article-title":"Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease","volume":"11","author":"Gabow","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.024_b0175","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cgh.2014.07.051","article-title":"Liver involvement in early autosomal-dominant polycystic kidney disease","volume":"13","author":"Hogan","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.11.024_b0180","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ajog.2011.06.056","article-title":"The state of hormonal contraception today: established and emerging noncontraceptive health benefits","volume":"205","author":"Maguire","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jhep.2017.11.024_b0185","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/ndt\/gfv417","article-title":"Risk factors for progressive polycystic liver disease: where do we stand?","volume":"31","author":"D'Agnolo","year":"2016","journal-title":"Nephrol Dialysis Transplant"},{"key":"10.1016\/j.jhep.2017.11.024_b0190","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00000658-199703000-00008","article-title":"Adult polycystic liver disease: is fenestration the most adequate operation for long-term management?","volume":"225","author":"Gigot","year":"1997","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2017.11.024_b0195","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jhep.2014.06.024","article-title":"Development and validation of a polycystic liver disease complaint-specific assessment (POLCA)","volume":"61","author":"Temmerman","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.024_b0200","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hep.28545","article-title":"Development and validation of a disease-specific questionnaire to assess patient-reported symptoms in polycystic liver disease","volume":"64","author":"Neijenhuis","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.024_b0205","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jhep.2014.12.017","article-title":"Reply to: \u201cDevelopment and validation of a polycystic liver disease complaint-specific assessment (POLCA) \u2013 use of the Delphi technique for content validation\u201d","volume":"62","author":"Temmerman","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.024_b0210","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jhep.2014.11.043","article-title":"Development and validation of a polycystic liver disease complaint-specific assessment (POLCA) \u2013 use of the Delphi technique for content validation","volume":"62","author":"Trevisol","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.024_b0215","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jhep.2017.11.024_b0220","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/j.cgh.2015.05.039","article-title":"Lanreotide reduces liver volume, but might not improve muscle wasting or weight loss, in patients with symptomatic polycystic liver disease","volume":"13","author":"Temmerman","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.11.024_b0225","doi-asserted-by":"crossref","first-page":"e0144526","DOI":"10.1371\/journal.pone.0144526","article-title":"Clinical correlates of mass effect in autosomal dominant polycystic kidney disease","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2017.11.024_b0230","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1399-0004.1986.tb00565.x","article-title":"Adult polycystic liver and kidney diseases are separate entities","volume":"30","author":"Karhunen","year":"1986","journal-title":"Clin Genet"},{"key":"10.1016\/j.jhep.2017.11.024_b0235","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/liv.12430","article-title":"Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume","volume":"34","author":"Wijnands","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.11.024_b0240","first-page":"696A-A","article-title":"Hepatic venous outflow obstruction in polycystic liver disease: impact on pathology and intra and postoperative course after liver resection","volume":"64","author":"Barbier","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.024_b0245","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.3748\/wjg.v19.i35.5775","article-title":"Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases","volume":"19","author":"Abu-Wasel","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.11.024_b0250","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1007\/s11605-012-1922-6","article-title":"Hemorrhagic hepatic cyst: report of a case and review of the literature with emphasis on clinical approach and management","volume":"16","author":"Fong","year":"2012","journal-title":"J Gastroint Surg"},{"key":"10.1016\/j.jhep.2017.11.024_b0255","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10140-013-1179-8","article-title":"Symptomatic and complicated nonhereditary developmental liver cysts: cross-sectional imaging findings","volume":"21","author":"Tonolini","year":"2014","journal-title":"Emerg Radiol"},{"key":"10.1016\/j.jhep.2017.11.024_b0260","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1148\/radiographics.9.2.2538868","article-title":"The CT appearance of cystic masses of the liver","volume":"9","author":"Murphy","year":"1989","journal-title":"Radiographics"},{"key":"10.1016\/j.jhep.2017.11.024_b0265","doi-asserted-by":"crossref","first-page":"W355","DOI":"10.2214\/AJR.10.5292","article-title":"Cystic lesions of the liver","volume":"196","author":"Vachha","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jhep.2017.11.024_b0270","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/ndt\/gfu227","article-title":"Diagnostic criteria in renal and hepatic cyst infection","volume":"30","author":"Lantinga","year":"2015","journal-title":"Nephrol Dialysis Transplant"},{"key":"10.1016\/j.jhep.2017.11.024_b0275","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5414\/CN108495","article-title":"18F-FDG PET\/CT during diagnosis and follow-up of recurrent hepatic cyst infection in autosomal dominant polycystic kidney disease","volume":"84","author":"Lantinga","year":"2015","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.jhep.2017.11.024_b0280","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1665-2681(19)31375-4","article-title":"Hemorrhagic liver cyst rupture: an unusual life-threatening complication of hepatic cyst and literature review","volume":"12","author":"Marion","year":"2013","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2017.11.024_b0285","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s10096-015-2361-6","article-title":"Cyst infection in autosomal dominant polycystic kidney disease: causative microorganisms and susceptibility to lipid-soluble antibiotics","volume":"34","author":"Suwabe","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jhep.2017.11.024_b0290","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1752-1947-4-2","article-title":"Spontaneous rupture of a large non-parasitic liver cyst: a case report","volume":"4","author":"Miliadis","year":"2010","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.jhep.2017.11.024_b0295","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4254\/wjh.v4.i12.406","article-title":"Complications arising in simple and polycystic liver cysts","volume":"4","author":"Macutkiewicz","year":"2012","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.024_b0300","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s11605-007-0182-3","article-title":"Inferior vena cava stenting: a safe and effective treatment for intractable ascites in patients with polycystic liver disease","volume":"11","author":"Grams","year":"2007","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.jhep.2017.11.024_b0305","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.11.024_b0310","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","article-title":"The long-term outcome of patients with polycystic liver disease treated with lanreotide","volume":"35","author":"Chrispijn","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2017.11.024_b0315","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/apt.13301","article-title":"Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials","volume":"42","author":"Neijenhuis","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2017.11.024_b0320","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/apt.12384","article-title":"Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data","volume":"38","author":"Temmerman","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2017.11.024_b0325","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/hep.24036","article-title":"Medical and surgical treatment options for polycystic liver disease","volume":"52","author":"Drenth","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.024_b0330","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2214\/AJR.16.16130","article-title":"Efficacy and safety of aspiration sclerotherapy of simple hepatic cysts: a systematic review","volume":"208","author":"Wijnands","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jhep.2017.11.024_b0335","first-page":"298","article-title":"Laparoscopic cyst fenestration in the treatment of polycystic liver disease","volume":"85","author":"Pante","year":"2014","journal-title":"Ann Ital Chir"},{"key":"10.1016\/j.jhep.2017.11.024_b0340","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s10620-007-0121-x","article-title":"Aspiration-sclerotherapy results in effective control of liver volume in patients with liver cysts","volume":"53","author":"van Keimpema","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2017.11.024_b0345","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.3748\/wjg.v13.i38.5052","article-title":"Surgical management of polycystic liver disease","volume":"13","author":"Russell","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.11.024_b0350","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/hepr.12560","article-title":"Comparison of volume-reductive therapies for massive polycystic liver disease in autosomal dominant polycystic kidney disease","volume":"46","author":"Yang","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2017.11.024_b0355","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/gut.2004.046524","article-title":"The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection","volume":"54","author":"Schindl","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.11.024_b0360","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jamcollsurg.2015.12.051","article-title":"Outcomes and durability of hepatic reduction after combined partial hepatectomy and cyst fenestration for massive polycystic liver disease","volume":"223","author":"Chebib","year":"2016","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jhep.2017.11.024_b0365","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/jlts.2001.22178","article-title":"Liver transplantation for polycystic liver disease","volume":"7","author":"Pirenne","year":"2001","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jhep.2017.11.024_b0370","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jamcollsurg.2014.03.058","article-title":"A 20-year experience with liver transplantation for polycystic liver disease: does previous palliative surgical intervention affect outcomes?","volume":"219","author":"Baber","year":"2014","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jhep.2017.11.024_b0375","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1002\/lt.20974","article-title":"Model for end-stage liver disease (MELD) exception for polycystic liver disease","volume":"12","author":"Arrazola","year":"2006","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jhep.2017.11.024_b0380","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1002\/lt.20979","volume":"12","author":"Freeman","year":"2006","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jhep.2017.11.024_b0385","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/liv.13041","article-title":"Combined liver-kidney transplantation for polycystic liver and kidney disease: analysis from the United Network for Organ Sharing dataset","volume":"36","author":"Coquillard","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.11.024_b0390","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2013.03.004","article-title":"Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: Results from a randomized controlled trial","volume":"59","author":"Chrispijn","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.024_b0395","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2015.05.023","article-title":"Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease","volume":"63","author":"Munoz-Garrido","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.024_b0400","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jhep.2016.05.009","article-title":"Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial","volume":"65","author":"D'Agnolo","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.024_b0405","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.dld.2013.10.021","article-title":"The bile acid TGR5 membrane receptor: from basic research to clinical application","volume":"46","author":"Duboc","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2017.11.024_b0410","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/hep.29284","article-title":"TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases via cAMP\/Galphas signaling","volume":"66","author":"Masyuk","year":"2017","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817324492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817324492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T15:38:29Z","timestamp":1570376309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827817324492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0168827817324492"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2017.11.024","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical management of polycystic liver disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2017.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}